17 research outputs found
Synthesis of benzylpiperazine derivatives containing the pyrazine moiety with potential activity against M. tuberculosis/SĂntese de derivados da benzilpiperazina contendo a fracção pirazina com potencial actividade contra a M. tuberculosis
A tuberculose (TB) ainda Ă© um problema de saĂșde pĂșblica global, apesar dos esforços e recentes avanços na medicina e farmacologia. A Organização Mundial da SaĂșde estima que em 2018, 1,5 milhĂ”es de pessoas morreram em todo o mundo devido Ă tuberculose. Nesse contexto, Ă© urgente a busca por novas molĂ©culas que possam oferecer mais eficĂĄcia, menor tempo de tratamento, com menores efeitos adversos conta TB. O presente trabalho descreve a sĂntese de oito novas benzilpiperazinas contendo o nĂșcleo pirazina, com potencial atividade antituberculose. As molĂ©culas foram planejadas de maneira racional, utilizando-se a tĂ©cnica de hibridação molecular, a partir do fĂĄrmaco pirazinamida e do nĂșcleo benzilpiperazina. As substĂąncias propostas foram obtidas a partir de um processo sintĂ©tico simples e reprodutivo, em rendimentos baixos
3-(2H-1,3-Benzodioxol-5-ylmethÂyl)-2-(2-methÂoxyÂphenÂyl)-1,3-thiaÂzolidin-4-one
The title molÂecule, C18H17NO4S, features a 1,3-thiaÂzolidine ring that is twisted about the SâC(methylÂene) bond. With reference to this ring, the 1,3-benzodioxole and benzene rings lie to either side and form dihedral angles of 69.72â
(16) and 83.60â
(14)°, respectively, with the central ring. Significant twisting in the molÂecule is confirmed by the dihedral angle of 79.91â
(13)° formed between the outer rings. Linear supraÂmolecular chains along the a-axis direction mediated by CâHâŻO interÂactions feature in the crystal packing
Recommended from our members
EPMA-World Congress 2015: Bonn, Germany. 3-5 September 2015
Table of contents A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-Andrea Abraham, Olga Golubnitschaja A2 Integrated market access approach amplifying value of âRx-CDxâ Ildar Akhmetov A3 Disaster response: an opportunity to improve global healthcare Russell J. Andrews, Leonidas Quintana A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy Russell J. Andrews A5 The role of IDO in a murine model of gingivitis: predictive and therapeutic potentials Babak Baban, Jun Yao Liu, Xu Qin, Tailing Wang, Mahmood S. Mozaffari A6 Specific diets for personalised treatment of diabetes type 2 Viktoriia V. Bati, Tamara V. Meleshko, Olga B. Levchuk, Nadiya V. Boyko A7 Towards personalized physiotherapeutic approach Joanna Bauer, Ewa Boerner, Halina Podbielska A8 Cells, animal, SHIME and in silico models for detection and verification of specific biomarkers of non-communicable chronic diseases Alojz Bomba, Viktor O. Petrov, Volodymyr G. Drobnych, Rostyslav V. Bubnov, Oksana M. Bykova, Nadiya V. Boyko A9 INTERACT-chronic care model: Self-treatment by patients with decision support e-Health solution Hans-Peter Brunner-La Rocca, Lutz Fleischhacker, Olga Golubnitschaja, Frank Heemskerk, Thomas Helms, Tiny Jaarsma, Judita Kinkorova, Jan Ramaekers, Peter Ruff, Ivana Schnur, Emilio Vanoli, Jose Verdu A10 PPPM in cardiovascular medicine in 2015 Hans-Peter Brunner-La Rocca A11 Magnetic resonance imaging of nanoparticles in mice, potential for theranostic and contrast media development â pilot results Rostyslav V. Bubnov, Sergiy A. Grabovetskyi, Olena M. Mykhalchenko, Natalia O. Tymoshok, Oleksandr B. Shcherbakov, Igor P. Semeniv, Mykola Y. Spivak A12 Ultrasound diagnosis for diabetic neuropathy - comparative study Rostyslav V. Bubnov, Tetyana V. Ostapenko A13 Ultrasound for stratification patients with diabetic foot ulcers for prevention and personalized treatment - pilot results Rostyslav V. Bubnov, Nazarii M. Kobyliak, Nadiya M. Zholobak, Mykola Ya. Spivak A14 Project ImaGenX â designing and executing a questionnaire on environment and lifestyle risk of breast cancer John Paul Cauchi A15 Genomics â a new structural brand of predictive, preventive and personalized medicine or the new driver as well? Dmitrii Cherepakhin, Marina Bakay, Artem Borovikov, Sergey Suchkov A16 Survey of questionnaires for evaluation of the quality of life in various medical fields Barbara CieĆlik, Agnieszka Migasiewicz, Maria-Luiza Podbielska, Markus Pelleter, Agnieszka Giemza, Halina Podbielska A17 Personalized molecular treatment for muscular dystrophies Sebahattin Cirak A18 Secondary mutations in circulating tumour DNA for acquired drug resistance in patients with advanced ALK + NSCLC Marzia Del Re, Paola Bordi, Valentina Citi, Marta Palombi, Carmine Pinto, Marcello Tiseo, Romano Danesi A19 Recombinant species-specific FcΔRI alpha proteins for diagnosis of IgE-mediated allergies in dogs, cats and horses Lukas Einhorn, Judit Fazekas, Martina Muhr, Alexandra Schoos, Lucia Panakova, Ina Herrmann, Krisztina Manzano-Szalai, Kumiko Oida, Edda Fiebiger, Josef Singer, Erika Jensen-Jarolim A20 Global methodology for developmental neurotoxicity testing in humans and animals early and chronically exposed to chemical contaminants ArpinĂ© A. Elnar, Nadia Ouamara, Nadiya Boyko, Xavier Coumoul, Jean-Philippe Antignac, Bruno Le Bizec, Gauthier Eppe, Jenny Renaut, Torsten Bonn, CĂ©dric Guignard, Margherita Ferrante, Maria Liusa Chiusano, Salvatore Cuzzocrea, Gerard O'Keeffe, John Cryan, Michelle Bisson, Amina Barakat, Ihsane Hmamouchi, Nasser Zawia, Anumantha Kanthasamy, Glen E. Kisby, Rui Alves, Oscar Villacañas PĂ©rez, Kim Burgard, Peter Spencer, Norbert Bomba, Martin Haranta, Nina Zaitseva, Irina May, StĂ©phanie Grojean, Mathilde Body-Malapel, Florencia Harari, Raul Harari, Kristina Yeghiazaryan, Olga Golubnitschaja, Vittorio Calabrese, Christophe Nemos, Rachid Soulimani A21 Mental indicators at young people with attributes hypertension and pre-hypertension Maria E. Evsevyeva, Elena A. Mishenko, Zurida V. Kumukova, Evgeniy V. Chudnovsky, Tatyana A. Smirnova A22 On the approaches to the early diagnosis of stress-induced hypertension in young employees of State law enforcement agencies Maria E. Evsevyeva, Ludmila V. Ivanova, Michail V. Eremin, Maria V. Rostovtseva A23 ĐĄentral aortic pressure and indexes of augmentation in young persons in view of risk factors Maria E. Evsevyeva, Michail V. Eremin, Vladimir I. Koshel, Oksana V. Sergeeva, Nadesgda M. Konovalova A24 Breast cancer prediction and prevention: Are reliable biomarkers in horizon? Shantanu Girotra, Olga Golubnitschaja A25 Flammer Syndrome and potential formation of pre-metastatic niches: A multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease Olga Golubnitschaja, Manuel Debald, Walther Kuhn, Kristina Yeghiazaryan, Rostyslav V. Bubnov, Vadym M. Goncharenko, Ulyana Lushchyk, Godfrey Grech, Katarzyna Konieczka A26 Innovative tools for prenatal diagnostics and monitoring: improving individual pregnancy outcomes and health-economy in EU Olga Golubnitschaja, Jan Jaap Erwich, Vincenzo Costigliola, Kristina Yeghiazaryan, Ulrich Gembruch A27 Immunohistochemical assessment of APUD cells in endometriosis Vadym M. Goncharenko, Vasyl O. Beniuk, Olga V. Kalenska, Rostyslav V. Bubnov A28 Updating personalized management algorithm of endometrial hyperplasia in pre-menopause women Vadym M. Goncharenko, Vasyl O. Beniuk, Rostyslav V. Bubnov, Olga Melnychuk A29 The personified treatment approach of polimorbid patients with periodontal inflammatory diseases Irina A. Gorbacheva, Lyudmila Y. Orekhova, Vadim V. Tachalov A30 Ukrainian experience in hybrid war â the challenge to update algorithms for personalized care and early prevention of different military injuries Olena I. Grechanyk, Rizvan Ya. Abdullaiev, Rostyslav V. Bubnov A31 Tear fluid biomarkers: a comparison of tear fluid sampling and storage protocols Suzanne Hagan, Eilidh Martin, Ian Pearce, Katherine Oliver A32 The correlation of dietary habits with gingival problems during menstruation Cenk Haytac, Fariz Salimov, Servin Yoksul, Anatoly A. Kunin, Natalia S. Moiseeva A33 Genomic medicine in a contemporary Spanish population of prostate cancer: our experience Bernardo Herrera-Imbroda, Sergio del RĂo-GonzĂĄlez, Maria Fernanda Lara, Antonia Angulo, Francisco Javier Machuca Santa-Cruz A34 Challenges, opportunities and collaborations for personalized medicine applicability in uro-oncological disease Bernardo Herrera-Imbroda, Sergio del RĂo-GonzĂĄlez, Maria Fernanda Lara A35 Metabolic hallmarks of cancer as targets for a personalized therapy John Ionescu A36 Influence of genetic polymorphism as a predictor of the development of periodontal disease in patients with gastric ulcer and 12 duodenal ulcer Alfiya Z. Isamulaeva, Anatoly A. Kunin, Shamil Sh. Magomedov, Aida I. Isamulaeva A37 Challenges in diabetic macular edema Tatjana Josifova A38 Overview of the EPMA strategies in laboratory medicine relevant for PPPM Marko Kapalla, Juraj KubĂĄĆ, Olga Golubnitschaja, Vincenzo Costigliola A39 EPMA initiative for effective organization of medical travel: European concepts and criteria Vincenzo Costigliola, Marko Kapalla, Juraj KubĂĄĆ, Olga Golubnitschaja A40 Design and innovation in e-textiles: implications for PPPM Anthony Kent, Tom Fisher, Tilak Dias A41 Biobank in Pilsen as a member of national node BBMRI_CZ Judita KinkorovĂĄ, OndĆej TopolÄan A42 Big data in personalized medicine: hype and hope Matthias Kohl A43 The 3P approach as the platform of the European Dentistry Department (DPPPD) Anatoly A. Kunin, Natalia S. Moiseeva A44 The endometrium cytokine patterns for predictive diagnosis of proliferation severity and cancer prevention Andrii I. Kurchenko, Vasyl A. Beniuk, Vadym M. Goncharenko, Rostyslav V. Bubnov, Nadiya V. Boyko, Andriy M. Strokan A45 A monocyte-based in-vitro system for testing individual responses to the implanted material: future for personalized implant construction Julia Kzhyshkowska, Alexandru Gudima, Ksenia S. Stankevich, Victor D. Filimonov4, Harald KlĂŒter, Evgeniya M. Mamontova, Sergei I. Tverdokhlebov A46 Prediction and prevention of adverse health effects by meteorological factors: Biomarker patterns and creation of a device for self-monitoring and integrated care Ulyana B. Lushchyk, Viktor V. Novytskyy, Igor P. Babii, Nadiya G. Lushchyk, Lyudmyla S. Riabets, Ivanna I. Legka A47 Targeting "disease signatures" towards personalized healthcare Mira Marcus-Kalish, Alexis Mitelpunkt, Tal Galili, Neta Shachar, Yoav Benjamini A48 Influence of the skin imperfection on the personal quality of life and possible tools for objective diagnosis Agnieszka Migasiewicz, Markus Pelleter, Joanna Bauer, Ewelina DereĆ, Halina Podbielska A49 The new direction in caries prevention based on the ultrastructure of dental hard tissues and filling materials Natalia S. Moiseeva, Anatoly A. Kunin, Dmitry A. Kunin A50 The use of LED radiation in prevention of dental diseases Natalia S. Moiseeva, Yury A. Ippolitov, Dmitry A. Kunin, Alexei N. Morozov, Natalia V. Chirkova, Nakhid T. Aliev A51 Status of endothelial progenitor cells in diabetic nephropathy: predictive and preventive potentials Mahmood S. Mozaffari, Jun Yao Liu, Babak Baban A52 The status of glucocorticoid-induced leucine zipper protein in salivary gland in Sjögrenâs syndrome: predictive and personalized treatment potentials Mahmood S. Mozaffari, Jun Yao Liu, Rafik Abdelsayed, Xing-Ming Shi, Babak Baban A53 Maximal aerobic capacity - important quality marker of health Jaroslav NovĂĄk, Milan Ć tork, VĂĄclav Zeman A54 The EMPOWER project: laboratory medicine and Horizon 2020 Wytze P. Oosterhuis, Elvar Theodorsson A55 Personality profile manifestations in patientâs attitude to oral care and adherence to doctorâs prescriptions Lyudmila Y. Orekhova, Tatyana V. Kudryavtseva, Elena R. Isaeva, Vadim V. Tachalov, Ekaterina S. Loboda A56 Results of an European survey on personalized medicine addressed to directions of laboratory medicine Mario Pazzagli, Francesca Malentacchi, Irene Mancini, Ivan Brandslund, Pieter Vermeersch, Matthias Schwab, Janja Marc, Ron H.N. van Schaik, Gerard Siest, Elvar Theodorsson, Chiara Di Resta A57 MCI or early dementia predictive speech based diagnosis techniques Matus Pleva, Jozef Juhar A58 Personalized speech based mobile application for eHealth Matus Pleva, Jozef Juhar A59 Circulating tumor cell-free DNA as the biomarker in the management of cancer patients JiĆĂ PolĂvka jr., Filip JankĆŻ, Martin PeĆĄta, Jan DoleĆŸal, Milena KrĂĄlĂÄkovĂĄ, JiĆĂ PolĂvka A60 Complex stroke care â educational programme in Stroke Centre University Hospital Plzen JiĆĂ PolĂvka, Alena LukeĆĄovĂĄ, Nina MĂŒllerovĂĄ, Petr Ć evÄĂk, VladimĂr Rohan A61 Sleep apnea and sleep fragmentation contribute to brain aging Kneginja Richter, Lence Miloseva, GĂŒnter Niklewski A62 Personalised approach for sleep disturbances in shift workers Kneginja Richter, Jens Acker, Guenter Niklewski A63 Medical travel and innovative PPPM clusters: new concept of integration Olga Safonicheva, Vincenzo Costigliola A64 Medical travel and women health Olga Safonicheva A65 Continuity of generations in the training of specialists in the field of reconstructive microsurgery Maxim Sautin, Janna Sinelnikova, Sergey Suchkov A66 Telemonitoring of stroke patients â empirical evidence of individual risk management results from an observational study in Germany SongĂŒl Secer, Stephan von Bandemer A67 Womenâs increasing breast cancer risk with n-6 fatty acid intake explained by estrogen-fatty acid interactive effect on DNA damage: implications for gender-specific nutrition within personalized medicine Niva Shapira A68 Cytobacterioscopy of the gingival crevicular fluid as a method for preventive diagnosis of periodontal diseases Aleksandr Shcherbakov, Anatoly A. Kunin, Natalia S. Moiseeva A69 Use of specially treated composites in dentistry to avoid violations of aesthetics Bogdan R. Shumilovich, Zhanna Lipkind, Yulia Vorobieva, Dmitry A. Kunin, Anastasiia V. Sudareva A70 National eHealth system â platform for preventive, predictive and personalized diabetes care Ivica Smokovski, Tatjana Milenkovic A72 The common energy levels of Prof. Szent-Györgyi, the intrinsic chemistry of melanin, and the muscle physiopathology. Implications in the context of Preventive, Predictive, and Personalized Medicine Arturo SolĂs-Herrera, MarĂa del Carmen Arias-Esparza, Sergey Suchkov A73 Plurality and individuality of hepatocellular carcinoma: PPPM perspectives Krishna Chander Sridhar, Olga Golubnitschaja A74 Strategic aspects of higher medical education reforms to secure newer educational platforms for getting biopharma professionals matures Maria Studneva, Sihong Song, James Creeden, Đark Đandrik, Sergey Suchkov A75 Overview of the strategies and activities of the European Federation of Clinical Chemistry and Laboratory Medicine, (EFLM) Elvar Theodorsson, EFLM A76 New spectroscopic techniques for point of care label free diagnostics Syed A. M. Tofail A77 Tumor markers for personalized medicine and oncology - the role of Laboratory Medicine OndĆej TopolÄan, Judita KinkorovĂĄ, OndĆej Fiala, Marie KarlĂkovĂĄ, Ć ĂĄrka SvobodovĂĄ, Radek KuÄera, Radka FuchsovĂĄ, Vladislav TĆeĆĄka, VĂĄclav Ć imĂĄnek, Ladislav Pecen, Jan Ć oupal, Ć tÄpĂĄn SvaÄina2 A78 Modern medical terminology (MMT) as a driver of the global educational reforms Evgeniya Tretyak, Maria Studneva, Sergey Suchkov A79 Juvenile hypertension; the relevance of novel predictive, preventive and personalized assessment of its determinants Francesca M. Trovato, G. Fabio Martines, Daniela Brischetto, Daniela Catalano, Giuseppe Musumeci, Guglielmo M. Trovato A80 Proteomarkers Biotech George Th. Tsangaris, Athanasios K. Anagnostopoulos A81 Proteomics and mass spectrometry based non-invasive prenatal testing of fetal health and pregnancy complications George Th. Tsangaris, Athanasios K. Anagnostopoulos A82 Integrated Ecosystem for an Integrated Care model for Heart Failure (HF) patients including related comorbidities (ZENITH) JosĂ© VerdĂș, German GutiĂ©rrez, Jordi Rovira, Marta Martinez, Lutz Fleischhacker, Donna Green, Arthur Garson, Elena Tamburini, Stefano Cuomo, Juan Martinez-Leon, Teresa Abrisqueta, Hans-Peter Brunner-La Rocca, Tiny Jaarsma, Teresa Arredondo, Cecilia Vera, Giuseppe Fico, Olga Golubnitschaja, Fernando Arribas, Martina Onderco, Isabel Vara, on behalf of ZENITH consortium A83 Predictive, preventive and personalized medicine in diabetes onset and complication (MOSAIC project) JosĂ© VerdĂș, Francesco Sambo, Barbara Di Camillo, Claudio Cobelli, Andrea Facchinetti, Giuseppe Fico, Riccardo Bellazzi, Lucia Sacchi, Arianna Dagliati, Daniele Segnani, Valentina Tibollo, Manuel Ottaviano, Rafael Gabriel, Leif Groop, Jacqueline Postma, Antonio Martinez, Liisa Hakaste, Tiinamaija Tuomi, Konstantia Zarkogianni, on behalf of MOSAIC consortium A84 Possibilities for personalized therapy of diabetes using in vitro screening of insulin and oral hypoglycemic agents Igor Volchek, Nina Pototskaya, Andrey Petrov A85 The innovative technology for personalized therapy of human diseases based on in vitro drug screening Igor Volchek, Nadezhda Pototskaya, Andrey Petrov A86 Bone destruction and temporomandibular joint: predictive markers, pathogenetic aspects and quality of life Ălle Voog-Oras, Oksana Jagur, Edvitar Leibur, Priit Niibo, Triin JagomĂ€gi, Minh Son Nguyen, Chris Pruunsild, Dagmar Piikov, Mare Saag A87 Sub-optimal health management â global vision for concepts in medical travel Wei Wang A88 Sub-optimal health management: synergic PPPM-TCAM approach Wei Wang A89 Innovative technologies for minimal invasive diagnostics Andreas WeinhĂ€usel, Walter Pulverer, Matthias Wielscher, Manuela Hofner, Christa Noehammer, Regina Soldo, Peter Hettegger, Istvan Gyurjan, Ronald Kulovics, Silvia Schönthaler, Gabriel Beikircher, Albert Kriegner, Stephan Pabinger, Klemens Vierlinger A90 Rare disease diobanks for personalized medicine AyĆe YĂŒzbaĆıoÄlu, Meral ĂzgĂŒĂ§, Member of EuroBioBank - European Network of DNA, Cell and Tissue Banks for Rare Disease
Synthesis of Acrylic Acid Derivatives: A Fast, Multigram Scale Methodology via Ultrasound Irradiation / Obtenção de Derivados de Ăcidos AcrĂlicos: Uma Metodologia RĂĄpida, em Escala Multigrama, por Irradiação de Ultrassom
Derivados de ĂĄcidos acrĂlicos sĂŁo importantes substĂąncias quĂmicas encontradas em cosmĂ©ticos, revestimentos, adesivos, entre outros. AlĂ©m disso, essas substĂąncias sĂŁo amplamente utilizadas no desenvolvimento de novas molĂ©culas bioativas contra diversas doenças, tais como, esquistossomose, tuberculose, malĂĄria e cĂąncer. Devido Ă importĂąncia desse building block em diversas ĂĄreas da quĂmica, nĂłs reportamos uma metodologia rĂĄpida, em escala multigrama para a sĂntese de alguns derivados de ĂĄcidos acrĂlicos por irradiação de ultrassom
Study of the antimalarial properties of hydroxyethylamine derivatives using green fluorescent protein transformed Plasmodium berghei
A rapid decrease in parasitaemia remains the major goal for new antimalarial drugs and thus, in vivo models must provide precise results concerning parasitaemia modulation. Hydroxyethylamine comprise an important group of alkanolamine compounds that exhibit pharmacological properties as proteases inhibitors that has already been proposed as a new class of antimalarial drugs. Herein, it was tested the antimalarial property of new nine different hydroxyethylamine derivatives using the green fluorescent protein (GFP)-expressing Plasmodium berghei strain. By comparing flow cytometry and microscopic analysis to evaluate parasitaemia recrudescence, it was observed that flow cytometry was a more sensitive methodology. The nine hydroxyethylamine derivatives were obtained by inserting one of the following radical in the para position: H, 4Cl, 4-Br, 4-F, 4-CH3, 4-OCH3, 4-NO2, 4-NH2 and 3-Br. The antimalarial test showed that the compound that received the methyl group (4-CH3) inhibited 70% of parasite growth. Our results suggest that GFP-transfected P. berghei is a useful tool to study the recrudescence of novel antimalarial drugs through parasitaemia examination by flow cytometry. Furthermore, it was demonstrated that the insertion of a methyl group at the para position of the sulfonamide ring appears to be critical for the antimalarial activity of this class of compounds
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
BACKGROUND: Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut dysbiosis. Whether ATB also affects outcomes to chemo-immunotherapy combinations is still unknown. PATIENTS AND METHODS: In this international multicentre study, we evaluated the association between pATB, concurrent ATB (cATB) and overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in patients with non-small-cell lung cancer (NSCLC) treated with first-line chemo-immunotherapy at eight referral institutions. RESULTS: Among 302 patients with stage IV NSCLC, 216 (71.5%) and 61 (20.2%) patients were former and current smokers, respectively. Programmed death-ligand 1 tumour expression in assessable patients (274, 90.7%) was â„50% in 76 (25.2%), 1%-49% in 84 (27.9%) and <1% in 113 (37.5%). Multivariable analysis showed pATB-exposed patients to have similar OS {hazard ratio (HR) = 1.42 [95% confidence interval (CI): 0.91-2.22]; P = 0.1207} and PFS [HR = 1.12 (95% CI: 0.76-1.63); P = 0.5552], compared to unexposed patients, regardless of performance status. Similarly, no difference with respect to ORR was found across pATB exposure groups (42.6% versus 57.4%, P = 0.1794). No differential effect was found depending on pATB exposure duration (â„7 versus <7 days) and route of administration (intravenous versus oral). Similarly, cATB was not associated with OS [HR = 1.29 (95% CI: 0.91-1.84); P = 0.149] and PFS [HR = 1.20 (95% CI: 0.89-1.63); P = 0.222] when evaluated as time-varying covariate in multivariable analysis. CONCLUSIONS: In contrast to what has been reported in patients receiving single-agent ICIs, pATB does not impair clinical outcomes to first-line chemo-immunotherapy of patients with NSCLC. pATB status should integrate currently available clinico-pathologic factors for guiding first-line treatment decisions, whilst there should be no concern in offering cATB during chemo-immunotherapy when needed
Oltre Bovisa. Paesaggi in movimento
Sintesi della Relazione di progetto:
In coerenza con gli orientamenti del bando, tesi a definire â...un processo di intervento in grado di supportare, nel lungo periodo, tutte le operazioni necessarie al successo della trasformazioneâ,
Il progetto assume come elementi centrali per lâimpostazione dellâimpianto:
a. Le preesistenze storico-architettoniche-ambientali presenti nellâarea;
b. La presenza di spazi aperti significativi allâinterno e nellâimmediato intorno;
c. La consistenza degli apparati infrastrutturali a differenti scale di intervento.
OBIETTIVI:
âą 1.Ritornare al luogo : Persistenze e variazioni
âą 2. Definire il nuovo landscape unitario: Locale e globale
âą 3.Conferire qualitĂ formale a tutte le componenti : IdentitĂ e differenze
STRATEGIE
Per raggiungere tali obiettivi, il progetto adotta le seguenti strategie:
A- La strategia della âcontaminazioneâ
Il Ri-uso dellâesistente
B - La strategia della progressione
Un âprocessoâ incrementale
C- La strategia dellâ âinterazioneâ
Un procedimento relazionale
AZIONI A partire dalle strategie sopra esposte, il progetto procede cosĂŹ alla individuazione di âAZIONIâ specifiche, ponendo grande attenzione alle richieste emerse dallo studio sulla âprogettazione partecipataâ. In questa prospettiva individua alcuni temi specifici (in rapporto alle funzioni proposte), che costituiscono i riferimenti principali per lâindividuazione delle azioni stesse.
Il progetto si propone pertanto di operare un intervento di trasformazione dellâarea non tanto in termini di periferia da rinnovare, ma come potenziale âcentralitĂ â da riconoscere entro sistemi urbani in grande trasformazione. In questo senso e superando una visione urbana radiocentrica, Bovisa puĂČ essere riconosciuta oggi come una importante âsezioneâ generatrice lungo lâasse reale/virtuale definito dalla sequenza Expo, Fiera, Porta Nuova, Piazza della Repubblica, piazzale Susa, determinando di fatto le premesse per la costruzione di un nuovo assetto morfologico di natura multipolare, con baricentro nel rinnovato nodo Porta Nuova-Garibaldi.
A partire dalla figura regolatrice della âturbinaâ, il progetto si Ăš posto pertanto lâobiettivo di fissare le sezioni portanti del nuovo disegno dinamico sulle tracce dei vettori concorrenti dai 4 quadranti al baricentro virtuale (la nuova piazza), in modo da innervare lâintera superficie rendendola tridimensionale. Come uno scenario formato da grandi âquinteâ urbane, costituite secondo sequenze differenziali a densificazione crescente, il disegno procede dal naturale (bordo esterno) allâartificiale (la fascia dedicata al campus) delineando una sequenza di âstripsâ in grado di diventare le nervature portanti del sistema. Lâinsieme di tali quinte viene a comporre il disegno complessivo di un grande parco unitario formato da una sequenza di intervalli-corridoio verdi compresi tra i filari giĂ esistenti, cosĂŹ da presentare un alto diaframma arboreo sul bordo esterno ferroviario e un sistema di moduli leggeri a traliccio verso lâinterno, che si addensa in prossimitĂ dei fabbricati preesistenti, recuperati ad ospitare nuove funzioni .
- Le relazioni con il contesto vengono in questo modo garantite dalla nuova âpermeabilitĂ definita dalla progressiva âsmaterializzazioneâ del muro preesistente disposto lungo il âring ferroviarioâ secondo una successione ritmata di âportaliâ attrezzati a sostenere/contenere in progressione lâapparato infrastrutturale esistente (strada e ferrovia) e nuovo (tracciato tranviario e pista ciclabile).
OUTSIDE
Il principio insediativo
La âsezioneâ in questo caso viene adottata non solo come strumento di ricomposizione dei due versanti, ma come elemento strategico per ritrovare un nuovo principio insediativo che, lavorando per âtagliâ, da un lato mette in stretta relazione i due versanti secondo âsezioni trasversali generatriciâ, dallâaltro individua una successione di âintervalliâ âdistanziatoriâ, capaci di restituire al suolo il ruolo di autentico âconnettivo urbanoâ. Ogni sezione definisce la soglia significativa della transizione tra interno ed esterno e lavora differenti scale relazionali:
-alla scala locale, la sezione individuata dal ponte abitato contenente spazi espositivi e sportivi, che diviene importante asse di correlazione tra le due parti, connettendo i doppi versanti a partire da nodi strategici (lâarea gasometri allâinterno del parco, lâarea delle âresidenzeâ speciali allâesterno;
-alla scala territoriale, la sezione interferente la nuova stazione, che non solo definisce le soglie dâaccesso ai due versanti, ma individua un nodo strategico di connessione alla grande scala;
-alla scala urbana, la sezione lungo il cavalcavia Bacula, che viene coinvolto direttamente nel nuovo disegno a sud dellâarea di progetto, mettendo in relazione, alla quota del terreno, lo spazio commerciale con il nuovo parco di piazzale Lugano.
I quattro paesaggi:
1 | il paesaggio della memoria e della stratificazione, che opera secondo un principio di rigenerazione dei luoghi, recuperando da un lato alcuni edifici notevoli esistenti , dallâaltro coinvolgendoli in un principio costruttivo incrementale nuovo;
2 | il paesaggio della creativitĂ e della produzione, che opta per lâinnovazione funzionale dellâarea, in rapporto alle nuove richieste del quartiere;
3 | il paesaggio della conoscenza e dellâ innovazione, che orienta lâattenzione soprattutto sui nuovi luoghi del sapere e della conoscenza, in virtĂč di un rapporto molto stretto tra ricerca e impresa;
4 | il paesaggio dellâenergia e della sostenibilitĂ , che opta per una soluzione sostenibile sia dal punto di vista fisico-spaziale, che dal punto di vista sociale e infrastrutturale.
UN NUOVO MODELLO ENERGETICO
Il progetto opta per il risparmio energetico e promuove la produzione di energia da fonti rinnovabili, individuando un set di tecnologie sia convenzionali che innovative adatte al contesto considerato.
Il geotermico, che contribuirĂ alla purificazione dellâacqua di falda, integrando sistemi di trattamento per la rimozione di idrocarburi volatili.
La produzione di energia da biomasse, per la quale si sono ipotizzate soluzioni di phytoremediation e di coltivazione di energy crops, inserita in una filiera costante di monitoraggio in sito della contaminazione delle stesse biomasse controllato dal laboratorio previsto nel campus.
La produzione fotovoltaica, la cui superficie utile (messa a disposizione per i pannelli fotovoltaici) Ăš di oltre 35.000 mq. Tale superficie Ăš in grado di fornire quasi 7.000 MWhel/anno, ovvero il 31% del fabbisogno elettrico delle porzioni servite ad esclusione delle superfici con destinazione commerciale.
Considerando lâingente flusso pedonale, si pensa inoltre di dotare i varchi particolarmente frequentati di dispositivi che, sollecitati dal peso dei passanti, generino elettricitĂ che possa essere immagazzinata in una batteria usata per contribuire allâilluminazione, ricaricare piccoli dispositivi (cellulari, laptopâŠ) e per alimentare le bici elettriche